Navigation Links
FDA Mandates Tougher Warnings for Pain Pills
Date:7/7/2009

Drugs like Darvon, Darvocet have been linked to fatal overdoses

TUESDAY, July 7 (HealthDay News) -- Concerns about the possibility of fatal overdoses led U.S. health officials Tuesday to take several steps to limit the risk of using pain medications containing propoxyphene, including Darvon and Darvocet.

Manufacturers must strengthen the labels of propoxyphene-containing products by adding boxed warnings that emphasize the potential for overdose and developing medication guides to be given to each person filling or refilling a prescription.

The manufacturers must also conduct a new safety study to assess unanswered questions, such as how propoxyphene affects the heart when taken at higher-than-recommended doses, Dr. Janet Woodcock, director of the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, said during a news conference.

The FDA is also working with several health-care organizations to collect additional safety data on these products, Woodcock said, adding that "the data we accumulate could result in additional regulatory action."

Woodcock also announced that the FDA has denied a petition from the consumer advocacy group Public Citizen asking for a phased withdrawal of products containing propoxyphene.

"The reason for the denial is that FDA has determined that propoxyphene is an acceptable option for relief of mild-to-moderate pain when taken as directed," she said. "Moreover, FDA recognizes that other options clinicians might have for pain management come with their own safety concerns."

Propoxyphene-containing products have been linked to fatal overdoses, FDA officials said. Between 1959 and 2005, 91 deaths attributed to an overdose of these products have been recorded in the adverse-events database, said Dr. Gerald Dal Pan, head of the FDA's office of surveillance and epidemiology.

But that database would not necessarily register information on deliberate overdosing, Woodcock said.

Last month, European regulators called for the withdrawal of dextropropoxyphene from the market because people taking the 50-year-old drug have been dying from overdoses.

Dextropropoxyphene, which is called propoxyphene in the United States, is an opioid widely used to treat mild to moderate pain. It was first introduced in the United States in 1957 under the brand name Darvon and is marketed today by a wide number of generic drug makers.

Last week, an FDA advisory panel recommended that the popular prescription painkillers Vicodin and Percocet, which combine acetaminophen with an opiate narcotic, be banned.

Darvocet contains acetaminophen.

More information

The U.S. Food and Drug Administration has more on propoxyphene.



SOURCES: July 7, 2009, teleconference with Janet Woodcock, M.D., director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, and Gerald Dal Pan, M.D., director, office of surveillance and epidemiology, U.S. Food and Drug Administration


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. ACM Helps Medicaid Programs Comply With Federal Deficit Reduction Act Mandates
2. New Study: Health Insurance Mandates on Employers Hurt Low-Income Employees
3. CAHI Releases Updated Health Insurance Mandates in the States
4. Most Companies Oppose Single-Payer Health Care System, State Coverage Mandates
5. FDA Mandates Black Box Warning for Some Antibiotics
6. Economic Stimulus Bill Mandates Electronic Health Records for Every Citizen without Opt-out or Patient Consent Provisions
7. Economic Stimulus Bill Mandates Electronic Health Records for Every American by 2014 - With No Opt-out Provision
8. Refuting Misconceptions About Health Insurance Mandates
9. FDA Mandates New Warnings for Botox
10. Controlling Risk Mandates Health Insurance Reviews
11. Blood Pressure Tougher to Tame in Winter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... ... to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is making ... app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of his ... says, “The positive response to the Snapchat videos we started last month has been overwhelming. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery Center, Washington ... opening a brand new child and adolescent residential treatment center on June 1. ... even more specialized eating disorder treatment and access to life-saving care. , To ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
(Date:5/25/2016)... Florida , May 25, 2016 ... Conference & Expo earlier this month, the numbers and ... revenues continue to climb into the billions, more research ... newly released 4th Edition State of Legal Marijuana Markets ... a cannabis-focused data-analysis firm, much of the increase in ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology: